BioPharmaTrend
Latest News
All Topics
  • Artificial Intelligence
  • NeuroTech
  • Premium Content
  • Knowledge Center
Interviews
Companies
  • Company Directory
  • Sponsored Case Studies
  • Create Company Profile
More
  • About Us
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Subscribe
Login/Join
back to Directory

Systems Oncology

Systems Oncology logo

Website
https://www.systemsoncology.com
Founded
2015
Patents
7
Publications
365

Technologies

AI Companies (Drug Discovery) Pharmaceutical and Drug Discovery

At Systems Oncology, we believe that innovating cancer drug discovery requires the exponential power of AI to uncover deeper mechanistic insights into cancer biology. Equipped with advanced cognitive computing technologies, we are able to aggregate and mine disparate types of biomedical datasets to reveal novel contextual vulnerabilities in cancer, and collaborate with leading universities to exploit those vulnerabilities with cutting-edge agents. We then invest in the most promising experimental agents to demonstrate their therapeutic potential. Finally, we partner with pharmaceutical companies to transform innovative new agents into the next breakthrough cancer therapies.

Our multidisciplinary team includes world-class experts from fields ranging from mathematics and AI to systems biology and oncology, all guided by deep clinical development experience. The combined expertise and our revolutionary approach empower us to discover and develop the next generation of cancer therapies with unprecedented speed and precision.

cancer therapies bioengineering

#advertisement
ThermoFisher Scientific: Integrated genetic technologies for cell therapy development
#advertisement
Webinar: AI in Clinical Trials

 

R&D Platform

DEEPER INSIGHTS: Our unique ExpansiveAI cognitive computing system empowered our systems biologists to integrate, model, and to use machine learning to mine complex genomic and biomedical datasets to uncover novel targeting combinations that can drive complex disease mechanisms and therapy resistance. We then translate that genomic intelligence into single agent multi-modal combinatorial targeting drugs using our proprietary Arromer RNA therapeutic platform.

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
gnews  Google News
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Premium Content
  • BioTech Scout
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Membership
  • Advertise
  • Submit Company
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.